The necroptosis signature and molecular mechanism of lung squamous cell carcinoma
Aging · 2023
DOI: 10.18632/aging.205210 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging, 2023. Verfasst von Guo-Qiang Song und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary, Changxing County Hospital of Traditional Chinese Medicine, Huzhou, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
BACKGROUND: Given the poor prognosis of lung squamous cell carcinoma (LUSC), the aim of this study was to screen for new prognostic biomarkers. METHODS: The TGCA_LUSC dataset was used as the training set, and GSE73403 was used as the validation set. The genes involved in necroptosis-related pathways were acquired from the KEGG database, and the differential genes between the LUSC and normal samples were identified using the GSEA. A necroptosis signature was constructed by survival analysis, and its correlation with patient prognosis and clinical features was evaluated. The molecular characteristics and drug response associated with the necroptosis signature were also identified. The drug candidates were then validated at the cellular level. RESULTS: The TCGA_LUSC dataset included 51 normal samples and 502 LUSC samples. The GSE73403 dataset included 69 samples. 159 genes involved in necroptosis pathways were acquired from the KEGG database, of which most showed significant differences between two groups in terms of genomic, transcriptional and methylation alterations. In particular, CHMP4C, IL1B, JAK1, PYGB and TNFRSF10B were significantly associated with the survival (p < 0.05) and were used to construct the necroptosis signature, which showed significant correlation with patient prognosis and clinical features in univariate and multivariate analyses (p < 0.05). Furthermore, CHMP4C, IL1B, JAK1 and PYGB were identified as potential targets of trametinib, selumetinib, SCH772984, PD 325901 and dasatinib. Finally, knockdown of these genes in LUSC cells increased chemosensitivity to those drugs. CONCLUSION: We identified a necroptosis signature in LUSC that can predict prognosis and identify patients who can benefit from targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary, Changxing County Hospital of Traditional Chinese Medicine, Huzhou, China.
- Department of Pulmonary and Critical Care Medicine, Zigong First People’s Hospital, Zigong, China.
- Department of Radiotherapy, Changxing People’s Hospital, Huzhou, China.
- Department of Cancer Center, Changxing County Hospital of Traditional Chinese Medicine, Huzhou, China.
Zitieren
APA
Song, G. Q., Wu, H. M., Ji, K. J., He, T. L., Duan, Y. M., Zhang, J. W., & Hu, G. Q. (2023). The necroptosis signature and molecular mechanism of lung squamous cell carcinoma. Aging. https://doi.org/10.18632/aging.205210
Vancouver
Song GQ, Wu HM, Ji KJ, He TL, Duan YM, Zhang JW, et al. The necroptosis signature and molecular mechanism of lung squamous cell carcinoma. Aging. 2023. doi:10.18632/aging.205210
BibTeX
@article{Song2023,
author = {Song, Guo-Qiang and Wu, Hua-Man and Ji, Ke-Jie and He, Tian-Li and Duan, Yi-Meng and Zhang, Jia-Wen and Hu, Guo-Qiang},
title = {The necroptosis signature and molecular mechanism of lung squamous cell carcinoma},
journal = {Aging},
year = {2023},
doi = {10.18632/aging.205210}
}
EUVIMED